Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth

Malaria, schistosomiasis and leishmaniases are among the most prevalent tropical parasitic diseases and each requires new innovative treatments. Targeting essential parasite pathways, such as those that regulate gene expression and cell cycle progression, is a key strategy for discovering new drug l...

Full description

Bibliographic Details
Main Authors: Ming Jang Chua, Megan S.J. Arnold, Weijun Xu, Julien Lancelot, Suzanne Lamotte, Gerald F. Späth, Eric Prina, Raymond J. Pierce, David P. Fairlie, Tina S. Skinner-Adams, Katherine T. Andrews
Format: Article
Language:English
Published: Elsevier 2017-04-01
Series:International Journal for Parasitology: Drugs and Drug Resistance
Subjects:
Plasmodium
Schistosoma
Leishmania
Histone deacetylase
Panobinostat
Online Access:http://www.sciencedirect.com/science/article/pii/S2211320716301117

Internet

http://www.sciencedirect.com/science/article/pii/S2211320716301117

Similar Items